Associated Papers
Pharmacogenetic Implications for Antidepressant Therapy in Major Depression: A Systematic Review Covering 2019-2024.
Fornaguera A et al.
Journal of Clinical Medicine, 2025
Influence of Genetic Variation of GST, CYP, and ABC on the Safety and Efficacy of Cyclophosphamide-Based Therapy.
Yao ZW et al.
Clinical and Translational Science, 2025
CYP2B6 and ABCB1 genotypes predict methadone plasma exposure among patients on maintenance therapy against opioid addictions in Tanzania.
Mugusi S et al.
British Journal of Clinical Pharmacology, 2024
CYP2C19 Allele Frequencies in Over 2.2 Million Direct-to-Consumer Genetics Research Participants and the Potential Implication for Prescriptions in a Large Health System.
Ionova Y et al.
Clinical and Translational Science, 2020
The Prognostic Value of Combinations of Genetic Polymorphisms in the ITGB3, ITGA2, and CYP2C19*2 Genes in Predicting Cardiovascular Outcomes After Coronary Bypass Grafting.
Grinshtein YI et al.
Genetic Testing and Molecular Biomarkers, 2018
Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine.
Brown SA et al.
Journal of Personalized Medicine, 2018
A prospective observational study of CYP2C19 polymorphisms and voriconazole plasma level in adult Thai patients with invasive aspergillosis.
Chuwongwattana S et al.
Drug Metabolism and Pharmacokinetics, 2016
Genetic and Nongenetic Factors Affecting Clopidogrel Response in the Egyptian Population.
Khalil BM et al.
Clinical and Translational Science, 2016
Role of genetic factors on the effect of additional loading doses and two maintenance doses used to overcome clopidogrel hyporesponsiveness.
Latkovskis G et al.
Medicina (kaunas, Lithuania), 2014
Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease.
Tantry US et al.
Expert Review of Cardiovascular Therapy, 2013
Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness.
Scott SA et al.
The Pharmacogenomics Journal, 2012
Differences in genotype and allele frequency distributions of polymorphic drug metabolizing enzymes CYP2C19 and CYP2D6 in mainland Chinese Mongolian, Hui and Han populations.
Yin SJ et al.
Journal of Clinical Pharmacy and Therapeutics, 2012
Pharmacogenomics of clopidogrel: evidence and perspectives.
Yin T et al.
Thrombosis Research, 2011
Possible role of CYP2C9 & CYP2C19 single nucleotide polymorphisms in drug refractory epilepsy.
Lakhan R et al.
The Indian Journal of Medical Research, 2011
Analysis of pharmacogenetic traits in two distinct South African populations.
Ikediobi O et al.
Human Genomics, 2011
Time-saving multiplex detection of single nucleotide polymorphisms by ultrasensitive DNA microarray.
Ichikawa M et al.
Journal of Biochemistry, 2010
Genotype frequencies of selected drug metabolizing enzymes and ABC drug transporters among breast cancer patients on FAC chemotherapy.
Afsar NA et al.
Basic & Clinical Pharmacology & Toxicology, 2010
Platelet pharmacogenomics.
Zuern CS et al.
Journal of Thrombosis and Haemostasis : Jth, 2010
Frequencies of genotypes and alleles of the functional SNPs in CYP2C19 and CYP2E1 in mainland Chinese Kazakh, Uygur and Han populations.
Wang SM et al.
Journal of Human Genetics, 2009
Genetic determinants of response to clopidogrel and cardiovascular events.
Simon T et al.
The New England Journal of Medicine, 2009
Validation of in vitro cell models used in drug metabolism and transport studies; genotyping of cytochrome P450, phase II enzymes and drug transporter polymorphisms in the human hepatoma (HepG2), ovarian carcinoma (IGROV-1) and colon carcinoma (CaCo-2, LS180) cell lines.
Brandon EF et al.
Toxicology and Applied Pharmacology, 2006